Purinoceptor P2y12 Antagonists Pipeline Insight
DelveInsight’s, “Purinoceptor P2Y12 Antagonists - Pipeline Insight, 2022,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Purinoceptor P2Y12 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Purinoceptor P2Y12 Antagonists Understanding
Purinoceptor P2Y12 Antagonists: Overview
The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses. Defects of P2Y12R should be suspected when ADP, even at high concentrations (≥ 10 μm), is unable to induce full, irreversible platelet aggregation. P2Y12R also plays a role in inflammation: its role in the pathogenesis of allergic asthma has been well characterized. In addition, inhibition or genetic deficiency of P2Y12R has antitumor effects. Drugs inhibiting P2Y12R are potent antithrombotic drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Purinoceptor P2Y12 Antagonists R&D. The therapies under development are focused on novel approaches for Purinoceptor P2Y12 Antagonists.
Purinoceptor P2Y12 Antagonists Emerging Drugs Chapters
This segment of the Purinoceptor P2Y12 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Purinoceptor P2Y12 Antagonists Emerging Drugs
Prasugrel: Daiichi Sankyo
Prasugrel is a prodrug that is converted to an active and inactive metabolite by the hepatic CYP system. The active component (R- 138727) of the metabolites irreversibly blocks P2Y12 at ADP receptors, preventing GPIIb/IIIa receptor complex activation, thus reducing platelet aggregation and activation. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). Currently, it is in Preregistration stage of development to treat stroke.
Ticagrelor binds to an area on the P2Y12 receptor distinct from the ADP binding site. BRILINTA reversibly binds to the ADP P2Y12 receptor and prevents ADP from binding. This prevents the signal transduction and platelet activation that can lead to pathologic thrombus formation.
Further product details are provided in the report……..
Purinoceptor P2Y12 Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Purinoceptor P2Y12 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Purinoceptor P2Y12 Antagonists
There are approx. 4+ key companies which are developing the Purinoceptor P2Y12 Antagonists. The companies which have their Purinoceptor P2Y12 Antagonists drug candidates in the most advanced stage, i.e. Preregistration include, Daiichi Sankyo.
DelveInsight’s report covers around 4+ products under different phases of clinical development like
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Purinoceptor P2Y12 Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Purinoceptor P2Y12 Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Purinoceptor P2Y12 Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Purinoceptor P2Y12 Antagonists drugs.
Purinoceptor P2Y12 Antagonists Report Insights
- Purinoceptor P2Y12 Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Purinoceptor P2Y12 Antagonists Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Purinoceptor P2Y12 Antagonists drugs?
- How many Purinoceptor P2Y12 Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Purinoceptor P2Y12 Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Purinoceptor P2Y12 Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Purinoceptor P2Y12 Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?